1. Providing Constant Analgesia with OROS® Hydromorphone
Suneel Gupta, PhD, Gayatri Sathyan, PhD 
Journal of Pain and Symptom Management 
Volume 33, Issue 2, Pages S19-S24 (February 2007)
DOI: /j.jpainsymman
Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

2. Fig. 1
Fluctuating plasma concentrations associated with IR and biphasic controlled-release formulations of pain medications can result in breakthrough pain.
Journal of Pain and Symptom Management  , S19-S24DOI: ( /j.jpainsymman )
Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

3. Fig. 2 Cross-section of the OROS® patented Push-Pull™ pump.
Journal of Pain and Symptom Management  , S19-S24DOI: ( /j.jpainsymman )
Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

4. Fig. 3
Release rate of hydromorphone from OROS® hydromorphone is consistent across dose strengths.
Journal of Pain and Symptom Management  , S19-S24DOI: ( /j.jpainsymman )
Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

5. Fig. 4 Mean plasma hydromorphone concentration vs. time on log scale.
Journal of Pain and Symptom Management  , S19-S24DOI: ( /j.jpainsymman )
Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

6. Fig. 5
Plasma concentration vs. time profiles of IR hydromorphone and OROS® hydromorphone after single-dose administration.4
Journal of Pain and Symptom Management  , S19-S24DOI: ( /j.jpainsymman )
Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

7. Fig. 6
Steady-state plasma concentration vs. time profiles of IR hydromorphone and OROS® hydromorphone.4
Journal of Pain and Symptom Management  , S19-S24DOI: ( /j.jpainsymman )
Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions

8. Fig. 7
The pharmacokinetics of OROS® hydromorphone are minimally affected by food.13
Journal of Pain and Symptom Management  , S19-S24DOI: ( /j.jpainsymman )
Copyright © 2007 U.S. Cancer Pain Relief Committee Terms and Conditions